Lisa Purcell | Senior Vice President, Microbiology and Virology
Vir Biotechnology, Inc.

Lisa Purcell, Senior Vice President, Microbiology and Virology, Vir Biotechnology, Inc.

Lisa Purcell, Ph.D. has served as the Vice President of Microbiology and Virology and head of Vir’s Saint Louis site since December 2020. Dr. Purcell’s career has been dedicated to the development of therapies within the immunology and infectious disease areas, including those for SARS-CoV-2/COVID-19. From July 2008 to December 2020, Dr. Purcell worked in both the clinical and nonclinical areas at Regeneron Pharmaceuticals focusing on the development of drugs for infectious disease, allergy and inflammation. Dr. Purcell received her B.Sc. with Honors in Biology and M.Sc. in Ecotoxicology from the University of Prince Edward Island, her Ph.D. in Parasitology from McGill University and completed her postdoctoral training at Columbia University Vagelos College of Physicians and Surgeons.


Pre-Congress Workshops - November 27 @ 14:00

Workshop A - Antibodies: Discovery vs Computational Design

Series of presentations followed by panel discussion

Computational design of antibodies  - Dr Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory

Discovery & development of broad-spectrum antibodies for Flu, COVID & RSV - Dr Phillip Lovanti, Sr. Director of R&D, Aridis Pharmaceuticals

Machine learning models for design of antibodies - Dr Sai Pooja Mahajan, Senior Scientist, Prescient Design, Genentech

Computational and artificial intelligence-based methods for antibody development - Dr Philip Kim, Professor, Principal Investigator, Department of Molecular Genetics, University of Toronto

How are NITAGs & HTAs thinking about novel antibody products? Richard Hughes, Partner, Epstein, Becker & Green, Professorial Lecturer in Law, The George Washington University Law School




Day 1 - November 28 @ 16:50

Panel: Beyond Vaccines: Exploring the power and potential of prophylactic antibodies

last published: 02/Jan/24 12:15 GMT

back to speakers